VANCOUVER, BC, April 9, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 29, 2024, after market close on Monday, April 15, 2024.
Interested parties are invited to participate in the Company's Q2 2024 results conference call and webcast, which will be held on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time. During the call, Numinus executives will review the Company's performance and recent initiatives.
A question-and-answer session will follow management's prepared remarks. At this time, the operator will provide instructions for qualified equity analysts to submit questions. Investors are invited to submit questions by email to This email address is being protected from spambots. You need JavaScript enabled to view it.. A selection of questions will be answered by management on the call, and all emailed questions will be responded to by email.
To listen to the live webcast, please register at: https://events.q4inc.com/attendee/472052579
The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations/
To participate in the live conference call, please use the following dial-in information:
To avoid any delays in joining the call, please dial in at least five minutes before the call starts. If prompted, please provide conference passcode 3547386.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
| Last Trade: | C$0.03 |
| Daily Change: | -0.005 -16.67 |
| Daily Volume: | 54,769 |
| Market Cap: | C$8.010M |
June 07, 2024 May 30, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
